The global deuterated drugs market, valued at US$ 334.0 million in 2023, presents a robust growth pattern. With a projected valuation of US$ 871.8 million by 2032 at a CAGR of 11.25%, the market is ...
Watertown, Massachusetts Saturday, September 28, 2024, 18:00 Hrs [IST] ...
Leerink Partners analyst Roanna Ruiz maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) yesterday. The ...
New data show Talvey’s potential in multiple myeloma drug combinations. Elsewhere, AbbVie got more positive Parkinson’s drug ...
Enanta Pharmaceuticals announced positive topline results from a Phase IIa trial of EDP-323, its RSV replication inhibitor, ...
In a report released today, Roy Buchanan from JMP Securities reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report), ...
Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...
Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...
Enanta Pharmaceuticals has linked its respiratory syncytial virus (RSV) antiviral to significant reductions in viral load and ...
Discover Enanta Pharmaceuticals' groundbreaking patent for HBV-inhibiting compounds, offering new hope for effective hepatitis B treatments and improved patient outcomes.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that members of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback